Oncology Institute at the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Cancer. 2013 Aug 15;119(16):3084-91. doi: 10.1002/cncr.28143. Epub 2013 May 29.
Over the past 2 decades, significant progress has been made in the field of metastatic colorectal cancer (mCRC) regarding new imaging techniques, surgical interventions, and systemic therapy. It is not known whether the benefit from these interventions has extended overall survival (OS) within the general mCRC population. A population-based survival analysis of newly diagnosed patients who presented with mCRC was therefore performed.
Survival statistics were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with mCRC between 1988 and 2008. Demographic variables collected included age, race, and tumor grade. Survival was analyzed using the Kaplan-Meier method and extended Cox proportional hazard model as appropriate.
The study population consisted of 42,347 patients diagnosed with mCRC between 1988 and 2008 (52% women; mean age, 67 years). The 1- and 2-year estimated OS rates were 44% and 22%, respectively. Prognostic variables included race, sex, age, tumor location, and year of diagnosis. Median OS improved from 8 months to 14 months between 1988 and 2008. Significant improvements in OS were seen for all disease sites, but especially for descending colon cancers. Whereas the median OS increased by 13 months in patients ≤50 years of age and by 7 months in patients 51-70 years of age, the median OS of patients >70 years of age increased by only 1 month between 1988 and 2008.
There has been a continuous improvement in OS of patients diagnosed with mCRC between 1988 and 2008, especially for left-sided tumors. Little improvement has been seen in patients over 70 years of age.
在过去的 20 年中,转移性结直肠癌(mCRC)领域在新的成像技术、手术干预和系统治疗方面取得了重大进展。目前尚不清楚这些干预措施是否延长了一般 mCRC 人群的总生存期(OS)。因此,对新诊断为 mCRC 的患者进行了一项基于人群的生存分析。
从 1988 年至 2008 年期间,从监测、流行病学和最终结果(SEER)数据库中提取 mCRC 患者的生存统计数据。收集的人口统计学变量包括年龄、种族和肿瘤分级。使用 Kaplan-Meier 方法和扩展的 Cox 比例风险模型进行生存分析。
该研究人群由 1988 年至 2008 年间诊断为 mCRC 的 42347 例患者组成(52%为女性;平均年龄为 67 岁)。1 年和 2 年的估计 OS 率分别为 44%和 22%。预后变量包括种族、性别、年龄、肿瘤位置和诊断年份。OS 的中位数从 1988 年的 8 个月提高到 2008 年的 14 个月。所有疾病部位的 OS 均得到显著改善,但降结肠癌尤其明显。≤50 岁的患者 OS 中位数增加了 13 个月,51-70 岁的患者增加了 7 个月,而>70 岁的患者仅增加了 1 个月。
1988 年至 2008 年间,诊断为 mCRC 的患者的 OS 持续改善,特别是对于左侧肿瘤。70 岁以上患者的改善甚微。